Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas.

OBJECTIVES Paragangliomas have unique features in the mediastinum, in part due to their location. Because of their paucity, they have not been thoroughly investigated. We studied the clinical, pathological, immunohistochemical and molecular features of mediastinal paragangliomas. METHODS Immunohistochemistry, next-generation sequencing mutation panel and the Oncoscan assay were performed. RESULTS Twenty-four patients with mediastinal paraganglioma (7 men, 29.2%) had a median age of 45.5 years (19.8-72.2). Twenty-one (87.5%) paragangliomas were completely resected. Six (of 24, 25.0%) tumours were considered metastatic. Mitotic activity occurred in 11 (of 24, 45.8%) paragangliomas. Programmed death-ligand 1 (PD-L1) (n = 23) was expressed in 6 (26%) patients in 10% (n = 2) and 1% (n = 4) of tumour cells, respectively. SDHB expression was lost in 19 (of 22, 86.4%) cases. ATRX expression was lost in 11 (of 23, 47.8%) cases. Next-generation sequencing revealed a single pathogenic mutation in 10 (of 19) specimens including SDHB (n = 4), SDHD (n = 6), SDHC (n = 1), ATRX (n = 1), and ≥2 mutations in 2 cases [SDHC and TERT (n = 1); SDHB, ATRX and TP53 (n = 1)]. Germline mutation analysis revealed the same succinate dehydrogenase mutation (or lack thereof) as identified in the paraganglioma in 11 (of 12) cases. During a median follow-up (n = 21) of 4.8 years (0.8-14.9), 3 patients developed metastases; 4 patients died, at least 1 of disease. CONCLUSIONS Mediastinal paragangliomas can be associated with morbidity and mortality. Many mediastinal paragangliomas have been reported to be associated with syndromes such as multiple endocrine neoplasia, von Hippel-Lindau or succinate dehydrogenase syndrome with mutation profiles dominated by alterations in genes associated with these syndromes.

[1]  A. Tischler,et al.  Pathology and genetics of phaeochromocytoma and paraganglioma , 2018, Histopathology.

[2]  S. Albert,et al.  Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature. , 2017, International Journal of Cardiology.

[3]  R. Dina,et al.  Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior , 2017, Oncoimmunology.

[4]  A. Farzaneh-Far,et al.  Succinate dehydrogenase gene mutation with cardiac paraganglioma: multimodality imaging and pathological correlation. , 2017, European heart journal.

[5]  R. Jenkins,et al.  Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism , 2017, Acta Neuropathologica.

[6]  R. Trillo-Nouche,et al.  Percutaneous Coronary Intervention for Treatment of Paraganglioma With Coronary Vascularization. , 2017, JACC: Cardiovascular Interventions.

[7]  M. Seong,et al.  Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas , 2016, PloS one.

[8]  S. Y-Hassan.  Clinical Features and Outcome of Pheochromocytoma-Induced Takotsubo Syndrome: Analysis of 80 Published Cases. , 2016, The American journal of cardiology.

[9]  M. Merino,et al.  Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations , 2015, The American journal of surgical pathology.

[10]  M. Vaisman,et al.  Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches , 2015, Front. Endocrinol..

[11]  T. Fojo,et al.  Succinate dehydrogenase gene mutations in cardiac paragangliomas. , 2015, The American journal of cardiology.

[12]  Juan F. García,et al.  Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. , 2015, Journal of the National Cancer Institute.

[13]  H. Neumann,et al.  Profiling of Somatic Mutations in Phaeochromocytoma and Paraganglioma by Targeted Next Generation Sequencing Analysis , 2015, International journal of endocrinology.

[14]  R. Greenberg,et al.  Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas , 2014, Nature Communications.

[15]  W. Dinjens,et al.  Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations , 2014, Genetics in Medicine.

[16]  S. Sleijfer,et al.  Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. , 2014, Endocrine-related cancer.

[17]  M. Simpson,et al.  Germline FH mutations presenting with pheochromocytoma. , 2014, The Journal of clinical endocrinology and metabolism.

[18]  M. Kunnimalaiyaan,et al.  The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors. , 2012, Global journal of biochemistry.

[19]  C. Boedeker.  Paragangliomas and paraganglioma syndromes , 2012, GMS current topics in otorhinolaryngology, head and neck surgery.

[20]  P. Söderkvist,et al.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. , 2011, Endocrine-related cancer.

[21]  Lei Feng,et al.  Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.

[22]  C. Vocke,et al.  Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. , 2011, The Journal of clinical endocrinology and metabolism.

[23]  Herb Chen,et al.  The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer , 2010, Pancreas.

[24]  Herb Chen,et al.  Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells , 2009, World Journal of Surgery.

[25]  E. van Marck,et al.  An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. , 2009, The Lancet. Oncology.

[26]  A. Fojo,et al.  Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. , 2008, Endocrine-related cancer.

[27]  M. Abel,et al.  Mediastinal paragangliomas: the mayo clinic experience. , 2008, The Annals of thoracic surgery.